Jeong Hwal Rim, Lee Hae Sang, Hwang Jin Soon
Department of Pediatrics Hallym University, School of Medicine, Chuncheon, Korea.
Department of Pediatrics Ajou University, School of Medicine, Suwon, Korea.
Exp Clin Endocrinol Diabetes. 2019 Apr;127(4):234-239. doi: 10.1055/s-0043-125067. Epub 2018 Mar 5.
Luteinizing hormone (LH) is a useful parameter in diagnosing precocious puberty. The pubertal response of serum LH to a GnRH stimulation test is varied, and clinical symptoms of precocious puberty are sometimes disproportionate with serum LH concentrations. Many patients present in a state of precocious puberty that advances rapidly, but the post-GnRH peak LH remains prepubertal. LH receptor mutations are suspected of involvement in the non-classic type of central precocious puberty (CPP).
To examine the association between LHCGR polymorphism and non-classic CPP in subjects exhibiting a peak LH<5 IU/L on a GnRH stimulation test.
In total, 102 girls with non-classic CPP and 100 normal adult women were enrolled. All subjects underwent LHCGR gene analysis by the Sanger method, and patients and controls were compared. Auxological data and gonadotropin concentrations were analyzed in the 102 patients. Of these patients, 75 completed GnRH agonist treatment, and the treatment outcomes were analyzed.
A total of seven variants were identified, including two missense mutations (g.48698754 G/A and g.48688613 G/A) that were found in the patient group (no patients contained both mutations). In silico analysis of these missense mutations suggested the possibility of damaging the LHCGR. However, no significant association was found between the identified LHCGR variants and non-classic CPP. GnRH agonist treatment decreased bone age advancement and increased predicted adult height.
LHCGR gene polymorphisms do not appear to be a major causative factor for the relatively low concentration of LH in patients with non-classic CPP. GnRH agonist treatment improved clinical parameters in these patients.
促黄体生成素(LH)是诊断性早熟的一个有用参数。血清LH对促性腺激素释放激素(GnRH)刺激试验的青春期反应各不相同,性早熟的临床症状有时与血清LH浓度不成比例。许多患者表现为性早熟进展迅速,但GnRH刺激试验后LH峰值仍处于青春期前水平。LH受体突变被怀疑与非典型中枢性性早熟(CPP)有关。
研究GnRH刺激试验中LH峰值<5 IU/L的受试者中,促黄体生成素/绒毛膜促性腺激素受体(LHCGR)基因多态性与非典型CPP之间的关联。
共纳入102例非典型CPP女童和100例正常成年女性。所有受试者均采用桑格法进行LHCGR基因分析,并对患者和对照组进行比较。对102例患者的体格学数据和促性腺激素浓度进行分析。其中75例患者完成了GnRH激动剂治疗,并对治疗结果进行分析。
共鉴定出7个变异位点,其中包括2个错义突变(g.48698754 G/A和g.48688613 G/A),均在患者组中发现(无患者同时携带这两种突变)。对这些错义突变的计算机模拟分析表明,它们有可能破坏LHCGR。然而,未发现所鉴定的LHCGR变异与非典型CPP之间存在显著关联。GnRH激动剂治疗可减缓骨龄进展,并增加预测成年身高。
LHCGR基因多态性似乎不是非典型CPP患者LH浓度相对较低的主要致病因素。GnRH激动剂治疗改善了这些患者的临床参数。